Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
“At Ultragenyx, we aspire to make a positive impact in the communities where we operate and beyond. To achieve this, we do what’s right for the rare disease community we serve and for the communities where we live and work. As a company born and built in Marin, we have seen firsthand the important impact that Giving Marin has on local nonprofits and are proud to rejoin the community partnership as a 2025 Sponsor,” said Betsy Ricketts, vice president, policy, government and public affairs at Ultragenyx. Fellow longtime Marin resident, Dr. Emil D. Kakkis, built Ultragenyx around deep and meaningful engagements with patients and their caregivers to fully understand their needs. In just 15 years, the team has built one of the most robust and diverse clinical pipelines in rare disease.
For more information, visit ultragenyx.com